AbbVie makes $63B bid for Botox maker Allergan
AbbVie is buying Botox maker Allergan in a cash-and-stock deal valued at around $63 billion. The maker of the blockbuster immune disorder treatment Humira said Tuesday that it will…
AbbVie is buying Botox maker Allergan in a cash-and-stock deal valued at around $63 billion. The maker of the blockbuster immune disorder treatment Humira said Tuesday that it will…